Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ASP1012 |
| Synonyms | |
| Therapy Description |
ASP1012 is an oncolytic vaccinia virus modified to express a leptiin/IL-2 fusion protein, which potentially enhances antitumor immune response (Cancer Res (2025) 85 (8_Supplement_2): CT122, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ASP1012 | ASP-1012|ASP 1012|VET2 L2|VET2-L2|VET2L2 | ASP1012 is an oncolytic vaccinia virus modified to express a leptiin/IL-2 fusion protein, which potentially enhances antitumor immune response (Cancer Res (2025) 85 (8_Supplement_2): CT122, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06171178 | Phase I | ASP1012 + Pembrolizumab ASP1012 | A Study of ASP1012 in Adults With Solid Tumors | Terminated | USA | 0 |